Selecta Biosciences, Inc. Current Part of Debt

Current Part of Debt of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Debt growth rates and interactive chart. Current debt or short-term debt are a firm's financial obligations that are expected to be paid off within a year. It also includes the portion of long-term debt that is due within a year. It is a part of the overall indebtedness of a company, and is included in Debt/Equity and Debt/Assets ratios.


Highlights and Quick Summary

  • Current Part of Debt for the quarter ending December 30, 2020 was $908 Thousand (a 3.77% increase compared to previous quarter)
  • Year-over-year quarterly Current Part of Debt decreased by -94.88%
  • Annual Current Part of Debt for 2020 was $908 Thousand (a -95.29% decrease from previous year)
  • Annual Current Part of Debt for 2019 was $19.3 Million (a -9.86% decrease from previous year)
  • Annual Current Part of Debt for 2018 was $21.4 Million (a 425.82% increase from previous year)
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Debt of Selecta Biosciences, Inc.

Most recent Current Part of Debtof SELB including historical data for past 10 years.

Interactive Chart of Current Part of Debt of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Current Part of Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.91 $0.88 $10.03 $17.73 $0.91
2019 $19.28 $20.93 $21.55 $21.47 $19.28
2018 $21.39 $21.3 $21.39
2017 $4.61 $4.52
2016 $4.07 $2.91 $1.78 $4.07
2014 $2.57 $2.58

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.